StockNews.com Downgrades Danaher (NYSE:DHR) to Hold

Danaher (NYSE:DHR) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Saturday.

DHR has been the subject of a number of other research reports. TD Cowen increased their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. KeyCorp lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Stephens restated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a report on Friday. Finally, Royal Bank of Canada cut their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.95.

Danaher Trading Up 0.2 %

NYSE:DHR opened at $234.89 on Friday. Danaher has a 12 month low of $222.53 and a 12 month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average price of $246.92 and a 200-day moving average price of $257.43. The stock has a market cap of $169.66 billion, a price-to-earnings ratio of 44.83, a P/E/G ratio of 4.33 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the business posted $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities analysts predict that Danaher will post 7.5 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fort Pitt Capital Group LLC raised its position in shares of Danaher by 3.2% in the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after buying an additional 7,421 shares during the last quarter. Good Life Advisors LLC purchased a new stake in shares of Danaher during the 3rd quarter valued at approximately $217,000. Oak Thistle LLC acquired a new position in Danaher in the second quarter valued at approximately $363,000. Harvest Portfolios Group Inc. grew its position in Danaher by 1.2% in the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after acquiring an additional 2,465 shares during the period. Finally, Stifel Financial Corp raised its position in Danaher by 1.3% in the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.